Hope S. Rugo, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial

Posted: Thursday, December 7, 2017

Hope S. Rugo, MD, of the University of California, San Francisco, discusses the long-term follow-up of CALGB 40502/NCCTG N063H, a phase III study of weekly paclitaxel compared with weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.